Skip to main content
. 2016 Aug 13;9(4):e6565. doi: 10.17795/ijcp-6565

Figure 2. Evolution of ESR1 Mutations in ER + Breast Cancer with Hormone Therapy.

Figure 2.

ESR1 mutations are rare in primary ER + breast cancers, and are considerably enriched in metastatic, hormone therapy resistant breast tumors. Almost all of the mutations in the estrogen receptor are localized in the ligand binding domain (LBD) of the estrogen receptor and leads to constitutive activation of the protein. AF1: Activation Function 1; DBD: DNA binding domain; AF2: Activation function 2; LBD: Ligand binding domain.